Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Southern Energy Corp. Completes US$23.5 Million Financings and Royalty Sale (click to learn more) Cariboo Gold History Inspires Modern Discovery (CSE:GCC) (OTC:GCCFF) (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Breaking & Recent News Gemina Laboratories Ltd C.GLAB

Alternate Symbol(s):  GLABF

Healthcare Biotechnology Diagnostics & Research
Gemina Laboratories Ltd., a biotechnology company, engages in the research, development, and commercialization of in-vitro diagnostics in Canada. The company's products include LEGIO X COVID-19, a COVID-19 rapid antigen test; and LEGIO X Influenza AB, an influenza AB multiplex lateral flow test. It also develops respiratory syncytial virus and tuberculosis. Gemina Laboratories Ltd. was... see more

Recent & Breaking News (CSE:GLAB)

Canadian Investment Regulatory Organization Trade Resumption - GLAB

Canada NewsWire December 30, 2025

Canadian Investment Regulatory Organization Trading Halt - GLAB

Canada NewsWire December 30, 2025

Debenture Offering and Delisting

ACCESS Newswire December 30, 2025

Gemina Laboratories Announces Termination of Transaction

ACCESS Newswire October 1, 2025

CSE Bulletin: INDEX - CSE 25 INDEX QUARTERLY REBALANCING

Newsfile September 18, 2025

How one company is disrupting PoC testing

Jocelyn Aspa November 28, 2024

Gemina Laboratories Announces Private Placement

ACCESS Newswire November 13, 2024

Gemina Laboratories Strategic Update

ACCESS Newswire July 10, 2024

Gemina Laboratories Commences Trading on the OTCQB Market in the United States

ACCESS Newswire June 20, 2024

Gemina Labs Announces Addition to its IP Portfolio

ACCESS Newswire April 9, 2024

Gemina Laboratories Sign First Strategic License Agreement

ACCESS Newswire April 2, 2024

Gemina Labs Strategic Update: Focusing on Respiratory Infections and Strategic Partnerships

ACCESS Newswire March 21, 2024

Gemina Announces Closing of $910,000 Convertible Note Financing

ACCESS Newswire March 19, 2024

Gemina Labs Ltd Appoints Stifel as Financial Advisor

ACCESS Newswire November 6, 2023

Canadian Securities Exchange Reports August 2023 Performance Figures

Newsfile September 19, 2023

Gemina Laboratories Announces Major Breakthrough in Environmentally Friendly Lateral Flow Test Design by Removing the Requirement for Nitrocellulose

ACCESS Newswire July 25, 2023

Gemina Laboratories to Participate in Poster Session at American Association of Clinical Chemistry Annual Scientific Meeting

ACCESS Newswire June 15, 2023

Gemina Laboratories and ReadyGo Diagnostics Achieve Mycobacterium Tuberculosis Diagnosis in Saliva

ACCESS Newswire June 5, 2023

Gemina Labs Antibody Immobilization Chemistry Platform Demonstrates Major Lateral Flow Assay Performance Improvement

ACCESS Newswire May 17, 2023

Gemina Laboratories to Host Investor Webinar on March 30, 2023

ACCESS Newswire March 27, 2023

Podcasts